Dabigatranetexilat (1) – Pradaxa®
Prevention of venous thromboembolic events after hip or knee replacement and prevention of stroke and systemic embolism
Characteristics
| Start date | 01.12.2013 |
|---|---|
| Resolution | 17.04.2014 |
| INN | Dabigatranetexilat |
| Brand name | Pradaxa® |
| Pharm. company | Boehringer Ingelheim Pharma GmbH & Co. KG |
| G-BA Procedure ID | D-085 |
| ATC code | B01AE07 Direct thrombin inhibitors (B01AE) |
| DDD | 0.3 g O |
| Therapeutic area | Hematopoietic diseases Venous thromboembolism (VTE) |
| Reason for procedure | not completed: discontinued |
| Specialty | Patent/data protection expired |
Associated procedures
<< List of all resolutions